Shandra Eisenga Human Cell and Tissue Product Safety Act
Latest Action
Received in the Senate.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Shandra Eisenga Human Cell and Tissue Product Safety Act is a legislative proposal introduced in the 118th Congress aimed at addressing safety standards related to human cell and tissue products. While the official summary and full text of the bill are not available, the bill's title and policy area indicate a focus on health and safety regulations concerning human biological materials used in medical treatments or research. The bill was introduced in the House and subsequently received in the Senate but ultimately failed or expired without enactment as of December 2025.
This bill sought to enhance safety measures for human cell and tissue products but did not advance beyond initial stages in Congress and is no longer active.
- The bill is titled the Shandra Eisenga Human Cell and Tissue Product Safety Act, indicating a focus on safety regulations for human biological materials.
- It was introduced in the House during the 118th Congress and later received in the Senate.
- The bill did not pass and is listed as failed or expired as of December 2025.
['Patients receiving treatments involving human cell and tissue products', 'Healthcare providers and medical researchers working with human biological materials', 'Regulatory agencies responsible for overseeing health and safety standards in biological products']
['Lack of available full text and official summary limits understanding of specific provisions and regulatory requirements', 'Potential implementation challenges related to enforcement and compliance monitoring if safety standards were to be updated or expanded', 'Unclear funding mechanisms or authority changes due to absence of detailed legislative text']
The bill was introduced in the House during the 118th Congress and subsequently received in the Senate but did not advance to passage. The absence of detailed legislative text and summary suggests limited public information and possibly limited legislative momentum. The policy area of health and safety regulation of human cell and tissue products is a specialized and technical field within health legislation.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential improvements in patient safety if the bill had established stronger regulatory standards for human cell and tissue products.', 'Possible increased regulatory burden on healthcare providers and manufacturers involved with human biological materials.', 'Enhanced oversight responsibilities for federal health agencies if the bill had been enacted.']
The absence of an official summary and full bill text significantly limits transparency and public understanding of the bill's specific provisions and potential impacts. This lack of information complicates oversight and informed discussion. Additionally, the bill's failure to advance suggests limited legislative support or prioritization, which is relevant for assessing future prospects and resource allocation.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.